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SUMMARY: A number of antihypertensive drugs are known to be diabetogenic. This may contribute to less
than expected decrease in the incidence of coronary heart disease with reduction in blood pressure with treat-
ment in hypertensive patients. This study was aimed to determine the effects of a member, Valsartan, of a new
class of drugs, angiotensin II receptor blocker, on glucose induced insulin secretion. Male albino rat pancreases
were used. The isolated pancreases were perfused with Kreb's solution containing bovine albumin (200 mg/dl)
with low glucose (60 mg/dl) followed by high glucose (300 mg/dl) at a rate of 4 ml/min. The dose of Valsartan
used was based on the peak plasma level achieved in human at standard single oral dose of 80 mg daily, which
was 1.64 mg/L. Five treatment groups were used: Control group, Valsartan at 10%, Valsartan at 100% and Val-
sartan at 10 times of the 1.64 mg/L, and Diazoxide 10 µg/ml group. Insulin levels in the perfusate were meas-
ured by radioimmunoassay. Valsartan at all concentrations significantly increases glucose induced insulin
secretion (p < 0.05). Valsartan at 10 %, Valsartan at 100% and Valsartan at 10 times of the 16.4 mg/L, increases
glucose induced insulin secretion by 226.4 %, 161.7 % and 156.3 %, respectively. Diazoxide, significantly
inhibits glucose induced insulin secretion (p < 0.05). 
Valsartan at all concentrations enhances glucose-induced insulin secretion in isolated rat pancreas technique.
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Pharmacology
INTRODUCTION
A number of compounds used in the treatment of
hypertension have been shown to impair insulin release
(1-3). Disturbances of insulin release caused by antihyper-
tensive drugs may be partly responsible for what has been
termed the coronary artery disease paradox. This concept
refers to the fact that success in reducing blood pressure
in groups of hypertensive patients who are using antihy-
pertensive drugs fails to reduce mortality and morbidity
from coronary artery disease (4). Hypertensive patients
receiving pharmacological treatment (diuretics or beta-
blockers) had an increased the risk of developing diabetes
(5). A study on 12,550 non-diabetic adults who were fol-
lowed for 6 years, experienced in a significantly increased
risk (28%) of developing diabetes after treatment with beta
blockers in contrast to diuretics, calcium antagonists and
angio-tensin converting enzyme inhibitor (ACEI) (6). Sev-
eral large clinical trials namely The Captopril Primary Pre-
vention Project (CAPP) (7), Heart Outcomes Prevention
Evaluation (HOPE) (8), and Losartan for Interventions for
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ARB class on insulin release in vitro preparation. The in
vitro technique was chosen as it determines a direct effect
of valsartan on the isolated rat pancreas in responses to
glucose-induced insulin release. 
MATERIALS AND METHODS
Drugs and treatment studied
The rats' pancreases were divided into five groups (6 pan-
creases per group). There were three groups of rats' pancreases
treated with valsartan at three different concentrations. Another two
control groups were carried out on different set of pancreases.
There were a control group with no treatment and a group treated
with diazoxide (10 µg/ml). Valsartan (CGP 48933: an active form)
was obtained from Novartis Pharma AG Basel, Switzerland. Val-
sartan concentration was based on the peak plasma/serum con-
centration achieved in human subject with a single standard oral
dose of 80 mg (21). Valsartan was dissolved in 1 molar KOH solu-
tion and was then made up to three different concentrations in the
perfusate fluid namely, i) peak concentration achieved with a single
standard oral dose 80 mg daily in human (1.64 mg/L), ii) at 1/10 of
the above concentration (0.164 mg/L), and iii) at 10 times of the
above concentration (16.4 mg/L). Diazoxide was purchased from
Latoxan Corporation (rue Leon Blum, Valence France). Diazoxide
(10 µg/ml) was used as a positive control and is a known potent
inhibitor of insulin release. Diazoxide's molecular weight was
230.7. It is dissolved easily in methanol and slightly diluted in
aqueos base. A concentration of 10 µg/ml of diazoxide was pre-
pared in NaOH (10%) solution. The diazoxide solution was kept
from light throughout the study by protecting the conicals with alu-
minium foil. 
Surgical technique
Male Albino rats weighing approximately 250-350 gram
were used. The rats were fed a standard laboratory diet (BARAS-
TOC). The twelve hours fasted rats (water ad libitum) were anes-
thesized with pentobarbitone (60 mg/kg body weight)
intraperitoneally. The pancreas was dissected according to the
technique of Loubatieres et al. (22). 
Perfusion technique
Bovine serum albumin (RIA grade) was obtained from
Sigma Chemicals Company (St. Louis, Mo). The bovine albumin
(200 mg/dl) was added to Kreb's solution. The isolated pancreas
was perfused with Kreb's solution at 37°C containing bovine albu-
min (200 mg/dl) with low glucose (60 mg/dl) concentration for 5 to
10 minutes to stabilize the pancreas, and followed by taking a total
of 5 samples (one sample each minute). This was switched to
Kreb's solution containing high glucose (300 mg/dl) for a further
20 minutes. Samples were collected for 15 seconds at the begin-
ning of each minute and were then frozen and stored at -20°C for
future assay. The perfusate was bubbled with a mixture of 95%
oxygen and 5% carbon dioxide. The system was non-recirculating
and the perfusion was carried out using a roller pump at a con-
Endpoints in Hypertension (LIFE) (9) have demonstrated
that blockade of the renin-angiotensin system (RAS) pro-
tects against development of diabetes in at risk patients
with hypertension. The mechanism underlying this effect is
unknown.
The RAS has long been known best for its haemody-
namic regulation by means of two major angiotensin II
(Ang II) receptor subtypes, AT1 and AT2 (10). The two
definitive enzymes for this system are renin and
angiotensin-converting enzyme (ACE), which determine
the generation of the physiologically active peptide, Ang II.
The RAS plays an important role in maintenance of blood
pressure and electrolytes as well as in fluid balance. In
addition to circulation RAS, tissue RAS can act locally as a
paracrine and/or autocrine factor for the specific needs of
individual tissues independently of the circulating counter-
part. In recent years, existence of a local angiotensin-gen-
erating system in multiple tissue organs has been shown
(11,12). Activity of the local RAS is an important determi-
nant of structure and function in a range of organs, includ-
ing the heart (13), adrenals (14), gonads (15), and
pancreas (16). Recently, the evidence for the presence of
a local angiotensin-generating system in the islets of the
pancreas has been reported (17). This study demon-
strated an inhibitory role for locally produced Ang II on glu-
cose-stimulated insulin secretion, an effect mediated by
the AT1 receptors located on the surface of the islet beta
cells. Ang II may also influence islet blood flow regulation
in the pancreas, and hence influence insulin release in the
isolated rat pancreas study (18). The importance of locally
released Ang II in the regulation of both organ structure
and function has demonstrated in the islets Zucker diabetic
fatty rat (19). This means that blocking AT1 and/or AT2
receptor subtypes may influence the local angiotensin-
generating system. The blockades of Ang II action by
ACEI or angiotensin II receptor blocker (ARB) are com-
monly the medication of choice. It is however, to date, the
effects of direct inhibition on locally produced Ang II partic-
ularly by the ARB are largely unknown. The nonpeptide
ARB, valsartan, is potent, orally active and is selective for
the Ang II receptors subtype AT1 (20). The direct effect of
valsartan on insulin release has not been investigated thus
far. We hypothesized that based on previous evidences
(17-19) ARB may have a great potential in interrupting the
endocrine pancreatic function, probably the ability to inhibit
the RAS at receptor levels. For that reasons this study was
carried out to study the effect of valsartan, a member of
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stant rate of 4.0 ml/minute. Insulin secretion was assayed as inte-
grated insulin release in the first (1-5 minute) phase with low glu-
cose and the second phase (6-25 minute) with high glucose. 
Insulin measurement
The insulin in the perfusate was determined by a radioim-
munoassay technique by using Linco Rat Insulin RIA Kit (LINCO
Research, Inc. St. Charles, Missouri USA). This method utilizes
125I-labeled insulin and a rat insulin antiserum for the quantitative
determination of rat insulin in serum, plasma, perfusion fluid or
other tissue culture media. In this procedure, a fixed concentration
of labeled tracer antigen was incubated with a constant dilution of
antiserum such that the concentration of antigen binding sites on
the antibody was limited. If unlabeled antigen was added to this
system, there was competition between labeled tracer and unla-
beled antigen for the limited and constant number of binding sites
on the antibody. Thus, the amounts of tracer bound to antibody
were decreased as the concentration of unlabeled antigen
increases. This can be measured after separating antibody-bound
from free tracer and counting one or the other, or both fractions. A
standard curve was set up with increasing concentrations of stan-
dard unlabeled antigen and from this curve the amount of antigen
in unknown samples can be calculated by using a gamma
counter. The sensitivity of the assay was 0.1 ng/ml. The insulin
secretion at each time interval (minute) was expressed as ng
insulin per minute per pancreas.
Ethics
The ethic committee of the Faculty of Medicine of IIUM
approved the protocol of this study. All animals received humane
care according to the 'Guide for the Care and Use of laboratory
animals' by the National Academy of Sciences.
Statistical analysis
The data were given as means ± SEM from the six different
groups consisting of 6 pancreases per group. Statistical signifi-
cance was assessed with Mann-Whitney U statistical test and the
significance of the difference was taken at p < 0.05 by comparing
the results of valsartan with that of the control. All analyses were
performed with SPSS 11.5 statistical software for Windows.
RESULTS
Normal response of insulin release to low and
high glucose concentrations
Six pancreases were used in the control group. A
total of 6 samples were collected at low glucose concentra-
tions, whereas 19 samples at high glucose concentrations.
The details immuno-reactive insulin secretions are as
shown in Table 1. At low glucose concentration, the
release of insulin from the pancreas was approximately
0.31ng/minute. At high glucose concentration, insulin
Table 1: Effects of valsartan (0.164 mg/L, 1.64 mg/L and 16.4 mg/L) and positive control (diazoxide 10 µg/ml) on average insulin secre-
tion/minute/pancreas in low and high glucose perfusion.
Group Glucose
Concentration
Sample Mean  immuno-reactive of insulin
(ng/min)a ± SEM
Control
n = 6
Low (60 mg/dl) 1 - 6 0.31 ± 0.03
High (300 mg/dl) 7 - 25 6.56 ± 0.36
Valsartan
0.164 mg/L
n = 6
Low (60 mg/dl) 1 - 6 1.20 ± 0.04
High (300 mg/dl) 7 - 25 14.85 ± 1.70*
Valsartan
1.64 mg/L
n = 6
Low (60 mg/dl) 1 - 6 0.69 ± 0.04
High (300 mg/dl) 7 - 25 10.61 ± 1.25*
Valsartan
16.4 mg/L
n = 6
Low (60 mg/dl) 1 - 6 1.02 ± 0.05
High (300 mg/dl) 7 - 25 10.25 ± 1.26*
Diazoxide
10 µg/ml 
n = 6
Low (60 mg/dl) 1 - 6 0.23 ± 0.01
High (300 mg/dl) 7 - 25 1.15 ± 0.16*
* p < 0.05  Significant
aImmuno-reactive insulin in nanogram/minute
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secretion was approximately 6.56 ng/minute. The biphasic
response of insulin secretion to glucose was demonstrated
as shown in Figure 1. 
Effects of diazoxide on insulin release
Diazoxide is a potent inhibitor of insulin release. In
this preparation, diazoxide 10 µg/ml reduced the basal
insulin secretion to approximately 0.23 ng/minute with low
glucose, and with high glucose concentration, the release
of insulin was significantly reduced (1.15 ng/minute,
p<0.05) compared to the control. The biphasic response
was abolished (Figure 1). 
Effects of valsartan on insulin release
The 3 different concentrations of valsartan compared
to the control value resulted in a significant increase of
insulin secretion (p<0.05) (Table 1). The patterns of insulin
release to low and high glucose perfusion are as shown in
Figure 2. Valsartan at 1/10 of the peak concentrations have
been shown to stimulate insulin secretion greater than at
peak and high concentrations. The amount of immuno-
reactive insulin (ng/pancreas/19 minutes) for valsartan at
0.164 mg/L, 1.64 mg/L and 16.4 mg/L were 14.85 ng/min,
10.61 ng/min and 10.25 ng/min, respectively, and the per-
centage observed were 226.4%, 161.7% and 156.3% com-
pared to the control value, respectively (Figure 3).
DISCUSSION
The study was designed to measure the effects of
antihypertensive drugs on insulin release. The technique
in this study was adopted from that of Loubatieres et al.
(22). This in vitro experiment was performed to identify the
direct effects of the tested drugs on insulin release, an
important determinant for glucose metabolism. Although,
the study of insulin secretion can be performed in vivo (i.e.
oral glucose tolerance test) instead of in vitro, the effects
on insulin release observed in vivo are not necessarily due
to the direct action on the beta-cells of the islet Langer-
hans. Other factors such as the effects of other endoge-
nous mediators may be involved. In the present study, all
concentrations of valsartan stimulated insulin secretion in
isolated rat pancreas. The stimulation of insulin secretion
by valsartan in vitro may partly suggest that the effect was
exerted directly on the beta-islets cells of pancreas and/or
possibly on the microvessels of pancreatic islets. 
Valsartan has no agonist effect on the AT1 receptors
(21), however the present study has demonstrated that it
seems to induce insulin secretion. A possible explanation
for this is as follows. Firstly, Valsartan displaces Ang II from
AT1 subtype receptors, thus antagonizing the effects of
Ang II (23). The antagonistic effect of valsartan may sub-
sequently cause less inhibitory effect of Ang II on AT1
receptors on the endocrine, exocrine and vascular cells of
Figure 1: Effects of diazoxide (10 µg/ml) on insulin release (ng/min) in low and high glucose perfusion in isolated rat pancreas (n=6).
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pancreas. This is based on the fact that the presence of an
intrinsic RAS in the rat pancreas may play a role in the reg-
ulation of pancreatic functions (24). Therefore, the less
inhibitory effect of Ang II would subsequently increase
insulin release particularly in the presence of valsartan in
the high glucose concentration. Secondly, there is a possi-
bility that valsartan has an effect on microvessels of the
pancreas, in which it may play an important role in regulat-
ing insulin release. Carlsson et al. (18) found that the first
phase of insulin release was delayed in response to glu-
cose with the presence of Ang II (exogenous) in the
medium. This was presumably due to the vasoconstrictive
15
Figure 2: Effects of valsartan (0.164 mg/L, 1.64 mg/L and 16.4 mg/L) on insulin release (ng/min) in low and high glucose perfusion in iso-
lated rat pancreas (n=6).
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Figure 3: Effects of valsartan (0.164 mg/L, 1.64 mg/L and 16.4 mg/L) on average insulin/min/pancreas (Mean ± SEM) in low and high glu-
cose perfusion in isolated rat pancreas (n=6, *p<0.05).
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action of Ang II. With the presence of valsartan, it may
inhibit the vasoconstrictive effect of the basal intra-pancre-
atic Ang II. This would lead to vasodilatation of the intra-
pancreatic microvessels. Even though, the evaluations of
Ang II effects were beyond the scope of the present study,
the influence of Ang II on insulin release is still significant
(17). Thirdly, some of the hormones, neurotransmitters,
and neuropeptides were indirectly involved in the regula-
tion of insulin release. It is possible that valsartan may
inhibit the intra-pancreatic Ang II or neurotransmitters.
Thus modulates the insulin release. It has been demon-
strated that Ang II receptors influence prostaglandin syn-
thesis (25,26), which in turn may modulate secretion of
insulin and glucagons (27). On the other hand, Ang II may
also modulate the secretion of other regulatory pancreatic
hormones such as cholecystokinin, pancreatic polypeptide
or somatostatin, which then influence alpha-cell or beta-
cell functions. However, this needs to be shown by further
research.
Carlsson et al. (18) reported that the RAS is important
in regulation of islet blood flow and points to a pivotal role
of islet blood perfusion for an adequate insulin release. In
isolated perfused rat pancreas study (18), enalaprilate
affected neither basal nor glucose-stimulated insulin
release, whereas Ang II delayed the first phase of insulin
release in response to glucose. The effect of Ang II was
shown to be due to vasoconstriction, and suggests a cru-
cial role of intact islet blood perfusion for maintenance of
an adequate insulin release (18). These findings were fur-
ther supported by the fact that an intrinsic RAS was
demonstrated in the rat pancreas which may play a role in
the regulation of pancreatic functions (24). Despite the
putative presence of angiotensin receptors in the pancreas
(28), Ang II has been reported not to have marked effects
on the release of insulin or glucagon from isolated rat islets
(29). However, the islets used in these in vitro studies lack
both blood supply and innervation, which is likely to affect
their response to Ang II. In a human study, Ang II has
demonstrated a potent vasoconstrictor function, which
reduce the total, basal, and pulsatile insulin secretion at
pressor dose and tended to suppress insulin secretion at
subpressor dose in humans (30). The amount of insulin
released that was measured in this preparation may be
partly influenced by the inhibition effect of valsartan on Ang
II. Therefore, this may partly suggest that the presence of
the RAS component in the pancreas would be also
involved in the regulation of insulin release. A direct inter-
action of signaling of the AT1 receptor and insulin receptor
in the pathogenesis of insulin resistance was recently sug-
gested (31). The authors found that valsartan increased
insulin sensitivity and glucose uptake in skeletal muscle of
KK-Ay mice via stimulating the insulin signaling cascade
and consequent enhancement of GLUT4 translocation to
the plasma membrane (31). This finding might suggest the
involvement of ARB, valsartan in particular on insulin sen-
sitivity and insulin receptors. 
A potential effect of valsartan on insulin secretion is
intriguing as this agent may or may not provide clinically
meaningful progress toward lowering the development of
coronary artery disease in hypertensive subjects. The fact
that some of the antihypertensive drugs were known to
inhibit insulin release, means that the patients are predis-
posed to other risk factors of CHD. Our results showed that
valsartan produced no diabetogenic effect and is suitable
for the management of hypertensive and hypertensive dia-
betic patients. In conclusion, valsartan at all concentrations
based on the peak plasma concentration achieved with a
single standard oral dose of 80 mg daily stimulates insulin
secretion in isolated rat pancreas. These observations
may be of relevance in the management of hypertension,
especially in hypertensive subjects with diabetes.
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